29 June 2021: Articles
A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab
Unusual or unexpected effect of treatment, Adverse events of drug therapy
Sonya K. Kedzior E , Gabrielle Jacknin E , Andi Hudler E , Scott W. Mueller E , Tyree Heath Kiser A*DOI: 10.12659/AJCR.931702
Am J Case Rep 2021; 22:e931702
Table 1. Laboratory results on admission.
| Laboratory parameter | Value | Reference |
|---|---|---|
| Serum sodium | 123 | 133–145 mmol/L |
| Serum potassium | 7.1 | 3.5–5.1 mmol/L |
| Serum chloride | 85 | 98–108 mmol/L |
| Serum glucose | 1123 | 70–199 mg/dL |
| Anion gap | 34 | 4–16 mmol/L |
| Hemoglobin A1c | 8.3 | ≤5.6% |
| Beta hydroxybutyrate | >8.00 | ≤0.27 mmol/L |
| Lactate | 4.7 | 0.5–2.2 mmol/L |
| Venous pH | 6.943 | 7.330–7.430 |
| Venous pCO2 | 30 | 36–48 mmHg |
| Venous bicarbonate | 6.1 | 22–26 mmol/L |
| Serum c-peptide | 0.1 | 0.8–5.2 ng/mL |
| Glutamic acid decarboxylase | >250 | 0.0–5.0 IU/mL |
| (GAD65) antibody | ||
| T4 free | 1.05 | 0.89–1.76 ng/dL |
| Thyroid stimulating hormone (TSH) | 0.23 | 0.45–5.33 mIU/L |